國風新材(000859.SZ):熱塑性聚酰亞胺(TPI)複合膜研發按計劃順利推進,目前已進入小試階段
格隆匯8月31日丨國風新材(000859.SZ)於2023年8月31日接受特定對象調研,就“公司新產品研發進展情況”,公司回覆稱,2023年上半年,公司新產品芯片封裝用聚酰亞胺薄膜(COF封裝用高強高模PI薄膜)經下游客户試用反饋,產品綜合性能優秀,達到國際先進水平;高透高亮功能聚酯薄膜(BOPET高透高亮離保基膜)經過研發中心課題組技術攻關,突破關鍵技術難題,成功應用在OCA塗布等光學顯示領域;半導體封裝用光敏聚酰亞胺(PSPI)光刻膠研發取得階段性成果,目前已處於實驗室送樣檢測階段;熱塑性聚酰亞胺(TPI)複合膜研發按計劃順利推進,目前已進入小試階段。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.